Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

por Tahami Monfared, Amir Abbas, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Kang, Kang, Zhang, Quanwu
Publicado 2023

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial

por Tahami Monfared, Amir Abbas, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Aruffo, Elena, Zhang, Quanwu
Publicado 2023

Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study

por Chandler, Conor, Folse, Henri, Gal, Peter, Chavan, Ameya, Proskorovsky, Irina, Franco-Villalobos, Conrado, Yang, Yunyang, Ward, Alex
Publicado 2021

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

por Igarashi, Ataru, Azuma, Mie Kasai, Zhang, Quanwu, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Tomita, Kiyoyuki, Tahami Monfared, Amir Abbas
Publicado 2023